BioPharm International

CONTINUE TO SITE >

OR WAIT 15 SECS

COVID-19 UpdateAnalyticsDevelopmentDownstream ProcessingManufacturingOutsourcingQuality/GMPsUpstream Processing2020 Bio/Pharma Virtual Congress

Analytical MethodsBioBusinessCell Culture/FermentationContinuous ProcessingDrug DeliveryFill/FinishFormulationProcess ChromatographyProcess Control/PATProcess DevelopmentQA/QCSeparation and PurificationSingle-Use SystemsSupply Chain

All NewsTop NewsBio/Pharma NewsIndustry NewsSupplier NewsEvents

All PublicationsBioPharm International

Biopharma InsightsSponsored eBooksSponsored PodcastsSponsored VideosWhitepapers

EnewsMagazine

About Us
Advertise
Editorial Information
Contact Us
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions

© 2020 MJH Life Sciences and BioPharm International. All rights reserved.

Spotlight

COVID-19 Update
Analytics
Development
Downstream Processing
Manufacturing
Outsourcing
Quality/GMPs
Upstream Processing
2020 Bio/Pharma Virtual Congress

Analytical Methods
BioBusiness
Cell Culture/Fermentation
Continuous Processing
Drug Delivery
Fill/Finish
Formulation
Process Chromatography
Process Control/PAT
Process Development
QA/QC
Separation and Purification
Single-Use Systems
Supply Chain

About Us
Advertise
Editorial Information
Contact Us
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions

© 2020 MJH Life Sciences^™ and BioPharm International. All rights reserved.

Guest Editorial: EPO Saga to Augur Regulatory Change?

December 15, 2002

Gordon Kelley

Volume 15, Issue 1

by Gordon Kelley, BioPharm International magazine